...
首页> 外文期刊>Histopathology: Official Journal of the British Division of the International Academy of Pathology >Immunohistochemistry increases the accuracy of diagnosis of benign papillary lesions in breast core needle biopsy specimens.
【24h】

Immunohistochemistry increases the accuracy of diagnosis of benign papillary lesions in breast core needle biopsy specimens.

机译:免疫组织化学可提高乳腺核心穿刺活检标本中良性乳头状病变的诊断准确性。

获取原文
获取原文并翻译 | 示例
           

摘要

AIMS: Recent studies have suggested that benign papillary lesions without atypia [benign papilloma (BP)] diagnosed on breast core needle biopsy (CNB) may not require excision. However, most have studied only small numbers of cases and scant data are available on the utility of immunohistochemistry in the categorization of papillary lesions on CNB. In the largest published series of BP identified on CNB, we studied the impact of immunohistochemistry on the accuracy of a CNB diagnosis of BP. METHODS AND RESULTS: Breast CNBs (n = 129) with a diagnosis of papillary lesion were immunostained for calponin, p63 and cytokeratin 5/6. Haematoxylin and eosin and immunostained slides were independently reviewed by four breast pathologists. BP was the final excision diagnosis in 35 cases. With the use of immunohistochemistry, the positive predictive value (PPV) of BP diagnosis by the four individual pathologists increased from 72.7-83.3% (mean 79.2%) to 77.8-87.5% (82.1%), the negative predictive value (NPV) increased from 77.8-98.5% (88.6%) to 100% for all four participants and overall accuracy increased from 78.7-92.6% (84.7%) to 90.7-95.4% (92.8%). No case of invasive carcinoma was diagnosed as BP on CNB by any participant. The frequency of ductal carcinoma in situ following a BP diagnosis on CNB ranged from 2.5% to 4.8% (4%) but was only 0-3% (2.3%) after excluding cases that were radiologically suspicious for malignancy. CONCLUSIONS: Immunohistochemistry increases accuracy of BP diagnosis in CNB specimens. Benign papillary lesions diagnosed on CNB do not require excision in the absence of suspicious clinical/radiological findings.
机译:目的:最近的研究表明,在乳腺核心穿刺活检(CNB)中诊断出无异型性的良性乳头状病变[良性乳头状瘤(BP)]可能不需要切除。然而,大多数人仅研究了少数病例,关于免疫组织化学在CNB乳头状病变分类中的实用性的数据很少。在CNB上发现的最大的BP系列文献中,我们研究了免疫组织化学对CNB诊断BP准确性的影响。方法和结果:对诊断为乳头状病变的乳腺CNBs(n = 129)进行钙蛋白,p63和细胞角蛋白5/6免疫染色。苏木精和曙红以及免疫染色的载玻片由四位乳腺病理学家独立审查。最终诊断为BP的是35例。通过使用免疫组织化学,四位病理学家对BP诊断的阳性预测值(PPV)从72.7-83.3%(平均79.2%)增加到77.8-87.5%(82.1%),阴性预测值(NPV)增加从所有四个参与者的77.8-98.5%(88.6%)到100%,整体准确度从78.7-92.6%(84.7%)增加到90.7-95.4%(92.8%)。没有参与者将CNB诊断为BP浸润性癌。 BP在CNB上诊断为BP后,原位导管癌的发生率在2.5%至4.8%(4%)之间,但在排除放射学上可疑的恶性肿瘤后,其发生率仅为0-3%(2.3%)。结论:免疫组织化学提高了CNB标本中BP诊断的准确性。在没有可疑的临床/放射学发现的情况下,CNB诊断出的良性乳头状病变无需切除。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号